Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Agree. Lots of unrealistic expectations around this. Most blue sky jam tomorrow companies come to nothing. We are really lucky here to have something which is now selling well and has a real future and a company that will not need further fund raising/ share dilution. It takes on average seven years to get a product to market. We are there. I was happy to top up today.
Yes.Early 2025 launch for USA is mentioned and is a key piece of information. Nothing else much that is new in the RNS.
The bit about going concern is standard wording that has to be included and I would not be worried about that.
Not directly relevant but just saw an interesting article listing the top ten shares held by AJ Bell ISA millionaires. Haleon is one of those top ten. Perhaps fffers some reassurance that, if Haleon are involved with Eroxon, they know what they are doing, and we should be on to a winner.
From this LSE board:
FUM Short positions.
Open Short Positions in Futura Medical
There are currently no open short positions in Futura Medical.
We are pleased to share that #Eroxon is the winner of the Best Big Budget OTC Marketing Campaign Award at Citeline's OTC Marketing Awards
Go on the company website. Frequently asked questions. When are the next results due? See Financial Calendar page. Go to Financial calendar page 2024. It is blank.
Really good point about the Barder interview. I was going to say that I hope some folks will give the Board some credit, and also think about the implications that 580 (!) fake sites have been taken down already. As you say, with product roll out and legitimate access there will be much less demand for products from dodgy websites at inflated prices. The fact that there are so many fake sites popping up illustrates demand and should be taken as a good sign.
Gentlemen, I believe we may have witnessed lift off. It will all accelerate from here. Patience of long term holders about to be rewarded.
Exactly my thoughts Martin. We guessed that an RNS was on the way. Not quite what we expected but the appointed of a new director who has recently been involved in companies who were taken over is a pretty big hint.
"Roy brings a wealth of commercial experience in medical devices companies and
has a proven track record of successfully scaling companies and delivering
substantial value for shareholders. He has held leadership positions at a
number of publicly quoted med tech companies, including CEO of Optos plc, a
leading retinal imaging device manufacturer, from 2008 to 2016 until its sale
to Nikon for £259m in February 2015. From 2007 to 2008, Roy was CEO of Gyrus
Group plc, a leader in minimally invasive surgery and visualisation, until its
acquisition by Olympus Corporation in 2008 for $1.9 billion."
What price the takeover for FUM?
Is that an RNS I hear approaching?
I started 2023 by nominating this as my share for the year, fool that I am. All the signs were that things were finally going to come good. Launches across the world, actual sales accumulating, US launch. etc. All of these have happened and yet here we are at 26p . Who is baling out and who is hanging on, sure that 2024 will be the year when we spread the jam thickly? I remain optimistic but it is getting harder to maintain that confidence.
It has been so nice to see a couple of days of blue. We have had a torrid time recently. I would love to think that this is the start of a sustained rally but how often have we seen spikes up on news only to be followed by a steady drift back down over subsequent days and weeks? I remain very optimistic long term but I think that real sustained uplift in the SP will only occur with 1. publication of actual sales and profit figures. 2 US launch,and 3. a turnround in the general markets. AIM shares have had their worst performance in decades over recent months. All three of the above are likely to happen in the first part of 2024. There is a huge amount of cash which people have taken out of equities in the last year or two. Once the Bear market ends and people start to reinvest, it is likely that a lot of money will come in to growth shares. If the new bull market co incides with launch of Eroxon in the US and good sales and profits elsewhere, people could really pile into this share. Maybe that is wishful thinking - time will tell. Interested to hear contrarian views.
Neighbouring Saudi Arabia next? Report in August suggested Q4 launch this year for Saudi with full marketing campaign by Labatec. Some estimates that 10% of males there have ED. (20 million male population). UAE male population just shy of 7 million and unusually 68% of population there are male.
'It's unbelievable Jeff' to quote a well known pundit - (any similiarities here to names of board members/members of the remuneration committee are purely co incidental).
Numbers are mentioned in this interview
https://www.proactiveinvestors.co.uk/companies/news/1026789/futura-medical-on-track-for-a-profit-in-2025-after-strong-first-half-1026789.html
Yes, I think it was a joint venture between GSK and Pfizer. Ie the biggest players in pharmaceuticals. There was a Demerger last year when they spun the consumer health division off as Haleon.
Here is the morning RNS we have been waiting for. Haleon appointed to commercialise Eroxon in the US. 4 million up front to FUM, royalties on all sales and milestone payments up to 45 million.
Martinelwick - I have commented on this before. There is a lot of misinformation and frankly lazy journalism out there. A number of sources are misleadingly suggesting that Eroxon contains things which it absolutely does not - usually the reference is to the GTN which was in the original FUM product but is not in the current product. You mention Alprostadil, which is a vasodilator and has similar effects to GTN. The product which is now Eroxon was originally used as a comparator in a clinical trial which was testing the efficacy of the original GTN based product. As this product worked just as well, the GTN ( which has side effects) was dropped and Eroxon only contains the ingredients that others have listed - ingredients which cause the heating and cooling effect and increased blood flow without the need for traditional drugs such as GTN to achieve that increased blood flow. Even a website for GP education and information ( GP notebook) still has wrong information about this, even though it was reviewed as supposedly accurate only last month.
The.Italian. Bucolic. Thanks, and yes, exactly.
And any chemist will tell you very quickly that Glycerin/glycerol is very different to compound nitrates of the substance.
Thanks Chizzy. That is interesting. Interesting partly because it is wrong. I have seen a few articles now perpetuating the wrong idea that Eroxon contains GTN. A lot of this article focusses on GTN, which is just not an ingredient in Eroxon. There has been some lazy journalism around this. Proably not important in the bigger scheme of things but expected better from Forbes. It misses the important point about how Eroxon developed out of earlier products. Med2005 contained GTN and what we now have in Eroxon was the 'placebo' in a trial of Med2005, and performed just as well. GTN has side effects , including headaches, nausea etc, and Eroxon does not . Good that Eroxon is getting a lot of publicity, but people need accurate information about what it actually is......